We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Adicet Bio, Inc. (ACET - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adicet Bio, Inc. is a member of the Medical sector. This group includes 1065 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ACET's full-year earnings has moved 28.2% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ACET has moved about 26.5% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 7.9% on average. This means that Adicet Bio, Inc. is performing better than its sector in terms of year-to-date returns.
Adma Biologics (ADMA - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 22.1%.
Over the past three months, Adma Biologics' consensus EPS estimate for the current year has increased 36.7%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 515 individual stocks and currently sits at #85 in the Zacks Industry Rank. On average, this group has gained an average of 4% so far this year, meaning that ACET is performing better in terms of year-to-date returns. Adma Biologics is also part of the same industry.
Adicet Bio, Inc. and Adma Biologics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Adicet Bio, Inc. (ACET - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adicet Bio, Inc. is a member of the Medical sector. This group includes 1065 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ACET's full-year earnings has moved 28.2% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ACET has moved about 26.5% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 7.9% on average. This means that Adicet Bio, Inc. is performing better than its sector in terms of year-to-date returns.
Adma Biologics (ADMA - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 22.1%.
Over the past three months, Adma Biologics' consensus EPS estimate for the current year has increased 36.7%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 515 individual stocks and currently sits at #85 in the Zacks Industry Rank. On average, this group has gained an average of 4% so far this year, meaning that ACET is performing better in terms of year-to-date returns. Adma Biologics is also part of the same industry.
Adicet Bio, Inc. and Adma Biologics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.